EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische Studie

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou, Margareth C Ozelo iD, Gili Kenet, Flora Peyvandi iD, Michael Wang, Bella Madan, Nigel S Key, Michael Laffan und 18 weitere

New England Journal of Medicine · 23.02.2023 · 388 (8) · 694-705

DOI: 10.1056/nejmoa2211075 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.02.2023. Verfasst von Johnny Mahlangu und 29 weiteren Autor:innen. Beteiligte Einrichtung: From the Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, and National Health …. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 209-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: BioMarin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AHumansMaleGene Transfer TechniquesHalf-LifeHemorrhageRecombinant Fusion ProteinsGene Therapy Agents

Substanzen

Factor VIIIRecombinant Fusion ProteinsValoctocogene Roxaparvovec

Autor:innen und Institutionen

  • From the Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, and National Health Laboratory Service, Johannesburg (J. Mahlangu); the Department of Pedi…

ORCID-Profile: Margareth C Ozelo, Flora Peyvandi

Förderung

  • BioMarin Pharmaceutical

Zitieren

APA

Mahlangu, J., Kaczmarek, R., von Drygalski, A., Shapiro, S., Chou, S. C., Ozelo, M. C., Kenet, G., Peyvandi, F., Wang, M., Madan, B., Key, N. S., Laffan, M., Dunn, A. L., Mason, J., Quon, D. V., Symington, E., Leavitt, A. D., Oldenburg, J., Chambost, H., …, & GENEr8-1 Trial Group (2023). Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. New England Journal of Medicine, 388(8), 694-705. https://doi.org/10.1056/nejmoa2211075

Vancouver

Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. New England Journal of Medicine. 2023;388(8):694-705. doi:10.1056/nejmoa2211075

BibTeX
@article{Mahlangu2023,
  author = {Mahlangu, Johnny and Kaczmarek, Radoslaw and von Drygalski, Annette and Shapiro, Susan and Chou, Sheng-Chieh and Ozelo, Margareth C and Kenet, Gili and Peyvandi, Flora and Wang, Michael and Madan, Bella and Key, Nigel S and Laffan, Michael and Dunn, Amy L and Mason, Jane and Quon, Doris V and Symington, Emily and Leavitt, Andrew D and Oldenburg, Johannes and Chambost, Hervé and Reding, Mark T and Jayaram, Kala and Yu, Hua and Mahajan, Reena and Chavele, Konstantia-Maria and Reddy, Divya B and Henshaw, Joshua and Robinson, Tara M and Wong, Wing Yen and Pipe, Steven W and GENEr8-1 Trial Group, GENEr8-1 Trial Group},
  title = {Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {8},
  pages = {694--705},
  doi = {10.1056/nejmoa2211075}
}
Kostenlos starten →